President Donald Trump said his administration is pressuring pharmaceutical companies to break up childhood vaccines into ...

FDA approved KERENDIA (finerenone) as the first new treatment in 30 years for adults with chronic kidney disease associated ...

GLP-1 drugs, including Wegovy, Zepbound, and Foundayo, help patients lose weight by mimicking a hormone that makes the body ...

Tempus AI shares pulled back Friday after a five-day rally of nearly 40% driven by CEO Eric Lefkofsky's reimbursement projections at the ...

The life sciences industry is entering a period in which artificial intelligence is increasingly becoming part of how ...

Vera Therapeutics, Inc. ( VERA) reported that in the pivotal ORIGIN 3 trial of TRUTAKNA (atacicept-vymj), an FDA-approved dual BAFF and APRIL inhibitor, it stabilised kidney function and prevented ...

GSK slides 1.82% today to GBX1865.50 despite ongoing progress in oncology and vaccines, with volatility remaining elevated.

Tempus AI (TEM) stock jumped 15% Thursday after CEO projected up to $400M in Medicare revenue. The stock has rallied 92% since its July low of $41.55.

Tempus AI (TEM) stock jumped 15% Thursday after CEO outlined Medicare revenue expectations up to $400M. Shares have surged 92% since July bottom.

Tempus AI (TEM) stock surged 15% Thursday as CEO outlined up to $400M in Medicare revenue. TEM is up 92% from its July low.

The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall ...